BRIEF — Sobi's Ravicti reimbursed in England

Rare diseases specialist Swedish Orphan Biovitrum (STO:SOBI) has secured reimbursement from the National Health Service (NHS) in England for Ravicti (glycerol phenylbutyrate) for the management of urea cycle disorders (UCDs).

This is the first liquid formulation of phenylbutyrate to be offered to patients via commissioning centers across England.

Robin Lachmann, consultant in inherited metabolic diseases, University College London Hospitals, said: “The reimbursement of glycerol phenylbutyrate means that we have a new management tool that may benefit our UCD patients and help to advance their care.”

Sobi has also gained reimbursement for Ravicti from the Irish authorities and NHS Scotland this month.